Abstract 073: Maximizing Sacubitril/Valsartan Clinical Benefit Under Budget Constraints [Session Title: Poster Session I]

Conclusions: In healthcare settings under budget constraints, payers can maximize clinical outcomes in HF patients, by prioritizing sacubitril/valsartan therapy to sub-populations that have demonstrated higher benefit in the PARADIGM-HF trial. Advocating the reduction of sacubitril/valsartan prices could enable wider populations to benefit from this promising therapy.

http://circoutcomes.ahajournals.org/cgi/content/short/10/Suppl_3/A073?rss=1

Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Arbel, R., Hammerman, A., Triki, N., Weinstein, J. M., Grrenberg, D. Tags: Session Title: Poster Session I Source Type: research